EMA (EU)
EVENT
Workshop on advancing proof-of-concept data in paediatric oncology drug development
Published: 9/21/2026Detected: 9/12/2026
Summary preview
Workshop to inform the development of a future EMA reflection paper on what constitutes adequate proof-of-concept evidence for anti-cancer medicinal products in paediatric patients.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountoncology
pediatrics
clinical
safety
#EMA
#paediatric oncology
#proof-of-concept
#reflection paper
#public consultation
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026